MEHD7945A clinical trials
Also written MEHD7945A and Duligotuzumab.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses MEHD7945A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Fluorouracil (1) · Carboplatin (1) · Cisplatin (1) · Paclitaxel (1) · Cobimetinib (1)
Studies
Open first, then newest update. How each study uses MEHD7945A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial TumorsCompletedPhase 1Genentech, Inc.NCT01207323Written as MEHD7945A
- A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)CompletedPhase 1Genentech, Inc.NCT01911598Written as MEHD7945A
- Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)CompletedPhase 2Genentech, Inc.NCT01652482Written as MEHD7945A
- A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And NeckCompletedPhase 2Genentech, Inc.NCT01577173Written as MEHD7945A
- A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRASCompletedPhase 1Genentech, Inc.NCT01986166Written as MEHD7945A